Drugs /

fhd-609

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for fhd-609

Fhd-609 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating fhd-609, 1 is phase 1 (1 open).

SS18-SSX1 Fusion, SS18-SSX2 Fusion, and SS18-SSX2B Fusion are the most frequent biomarker inclusion criteria for fhd-609 clinical trials.

Synovial sarcoma is the most common disease being investigated in fhd-609 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Fhd-609
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating fhd-609 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Target(s) [2]:
BRD9

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.